• Editorial •
Applications and advances of magnetic resonance imaging in diagnosing liver disease
DOI:10.3969/j.issn.1674-8034.2014.05.S1.003.
| [Abstract] Liver disease is highly prevalent in China. Besides the well-known chronic viral liver disease, increasing incidence of non-alcoholic fatty liver disease (NAFLD) and alcohol liver disease (ALD) has also been well documented in China, which can progress to end-stage liver disease characterized by severe hepatitis, liver cirrhosis and the eventual development of liver cancer. Physicians aimed at decreasing the mortality rate and improving the prognosis of chronic liver disease. Recently, with the update of pulse sequence and renewal of MR scanner, MR has become the irreplaceable modality of detecting liver disease, especially for quantifying fatty liver disease, liver fibrosis, cirrhosis and differentiating liver tumor, etc. This paper summarized the current status and new development of MRI in the application of liver disease. |
| [Keywords] Liver；Magnetic resonance imaging |
GUO Qi-yong * Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, China
SHI Yu Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, China
*Correspondence to: Guo QY, E-mail: guoqy@sj-hospital.org
Conflicts of interest None.
| Received 2014-08-20 |
| Accepted 2014-09-25 |
| DOI: 10.3969/j.issn.1674-8034.2014.05.S1.003 |
| DOI:10.3969/j.issn.1674-8034.2014.05.S1.003. |
[1]
庄辉．我国乙型肝炎防治现状及目标．中华内科杂志, 2008, 47(10): 793-795.
[2]
张华捷，庄辉，刘学恩．脂肪肝的流行病学研究进展．中华流行病学杂志, 2004, 25(7): 630-632.
[3]
杨钧，靳二虎，马大庆．肝脏磁共振成像的临床应用现状．世界华人消化杂志, 2010, 18(5): 467-471.
[4]
李加慧，李秋菊，于兵，等. DWI-MRI多b值水通道蛋白分子成像机理和方法学研究．中国临床医学影像杂志, 2014, 25(3): 186-189.
[5]
刘新疆，王滨．肝癌转移复发监测：磁共振扩散加权成像与外周血分子生物学技术研究进展．磁共振成像, 2012, 3(6): 471-477.
[6]
刘伟，杨军，邵康伟，等．扩散加权成像b值大小对肝脏良恶性病变的鉴别诊断价值．磁共振成像, 2011, 2(4): 283-289.
[7]
Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: clinical applications. J Comput Assist Tomogr, 2013. 37(6): 887-896.
[8]
Wang QB, Zhu H, Liu HL, Zhang B. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology, 2012, 56(1): 239-247.
[9]
Venkatesh SK, Yin M, Glockner JF, et al. MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol, 2008. 190(6): 1534-1540.
[10]
尤克增，沈智威，曹震，等．活体肝细胞凋亡代谢改变的质子磁共振频谱研究．磁共振成像, 2011, 2(4): 290-295.
[11]
Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol, 2014, 20(23): 7392-7402.
[12]
Meisamy S, Hines CD, Hamilton G, et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology, 2011, 258(3): 767-775.
[13]
Yu H, Shimakawa A, McKenzie CA, Brodsky E, Brittain JH, Reeder SB. Multiecho water-fat separation and simultaneous R2* estimation with multifrequency fat spectrum modeling. Magn Reson Med, 2008, 60(5): 1122-1134.
[14]
Tsurusaki M, Semelka RC, Zapparoli M, et al. Quantitative and qualitative comparison of 3.0 T and 1.5 T MR imaging of the liver in patients with diffuse parenchymal liver disease. Eur J Radiol, 2009, 72(2): 314-320.
[15]
Rosenkrantz AB, Oei M, Babb JS, Niver BE, Taouli B. Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging, 2011, 33(1): 128-135.
[16]
Frydrychowicz A, Lubner MG, Brown JJ, et al. Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging, 2012, 35(3): 492-511.
[17]
Bonnemain B. Nanoparticles: the industrial viewpoint. Applications in diagnostic imaging. Ann Pharm Fr, 2008, 66(5-6): 263-272.
